How to buy Eyenovia stock | $3.94

Eyenovia, Inc is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Eyenovia employs 27 staff and has a market cap (total outstanding shares value) of USD$141.6 million.

How to buy shares in Eyenovia

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Eyenovia. Find the stock by name or ticker symbol: EYEN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eyenovia reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$3.94, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Eyenovia, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Eyenovia. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Eyenovia share price

Use our graph to track the performance of EYEN stocks over time.

Eyenovia shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$3.94
52-week range	USD$1.11 - USD$6.12
50-day moving average	USD$3.9535
200-day moving average	USD$3.5321
Wall St. target price	USD$12
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.968

Buy Eyenovia shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Eyenovia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Eyenovia, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eyenovia price performance over time

Historical closes compared with the close of $3.94 from 2020-12-09

1 week (2021-01-15)	-39.94%
1 month (2020-12-23)	-31.72%
3 months (2020-10-22)	12.89%
6 months (2020-07-22)	8.24%

1 year (2020-01-22)	-13.97%
2 years (2019-01-22)	35.40%
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

Eyenovia financials

Gross profit TTM	USD$0
Return on assets TTM	-58.33%
Return on equity TTM	-118.7%
Profit margin	0%
Book value	$0.749
Market capitalisation	USD$141.6 million

TTM: trailing 12 months

Shorting Eyenovia shares

There are currently 50,026 Eyenovia shares held short by investors – that's known as Eyenovia's "short interest". This figure is 38.5% down from 81,366 last month.

There are a few different ways that this level of interest in shorting Eyenovia shares can be evaluated.

Eyenovia's "short interest ratio" (SIR)

Eyenovia's "short interest ratio" (SIR) is the quantity of Eyenovia shares currently shorted divided by the average quantity of Eyenovia shares traded daily (recently around 172503.44827586). Eyenovia's SIR currently stands at 0.29. In other words for every 100,000 Eyenovia shares traded daily on the market, roughly 290 shares are currently held short.

However Eyenovia's short interest can also be evaluated against the total number of Eyenovia shares, or, against the total number of tradable Eyenovia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eyenovia's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Eyenovia shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Eyenovia shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eyenovia.

Find out more about how you can short Eyenovia stock.

Eyenovia share dividends

We're not expecting Eyenovia to pay a dividend over the next 12 months.

Eyenovia share price volatility

Over the last 12 months, Eyenovia's shares have ranged in value from as little as $1.11 up to $6.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 2.087. This would suggest that Eyenovia's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Eyenovia overview

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Frequently asked questions

• What percentage of Eyenovia is owned by insiders or institutions?

  Currently 36.941% of Eyenovia shares are held by insiders and 9.144% by institutions.

• How many people work for Eyenovia?

  Latest data suggests 27 work at Eyenovia.

• When does the fiscal year end for Eyenovia?

  Eyenovia's fiscal year ends in December.

• Where is Eyenovia based?

  Eyenovia's address is: 295 Madison Avenue, New York, NY, United States, 10017

• What is Eyenovia's ISIN number?

  Eyenovia's international securities identification number is: US30234E1047

• What is Eyenovia's CUSIP number?

  Eyenovia's Committee on Uniform Securities Identification Procedures number is: 30234E104